CERTIFICATE

IMPACT FACTOR 2021

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

A comparative clinical evaluation of Aminobisphosphonates (Alendronate) in the management of periodontal osseous defects– A controlled clinical trial

Author: 
Dr. Cherry Chamria, Dr. Roshani Thakur and Dr. Devanand Shetty
Subject Area: 
Health Sciences
Abstract: 

Introduction: Deep intraosseous defects represent a major challenge for the clinician. Sites with intraosseous lesions have been shown to be at higher risk of disease progression in subjects who had not received periodontal therapy. Treatments of intrabony defects include scaling and root planing with surgical access flap. Additional osseous resective therapy and ⁄ or reconstructive therapy by means of the application of membranes, biological agents or grafting biomaterials can be used to correct the bone deformities induced by destructive periodontal disease and achieve regeneration. Host modulation is a promising new adjunctive therapeutic option for the management of periodontal diseases. The purpose of host modulation therapy is to restore the balance of proinflammatory or destructive mediators and anti-inflammatory or protective mediators to that seen in healthy individuals. Bisphosphonates are bone seeking agents that inhibit bone resorption by disrupting osteoclast activity. They interfere with osteoblast metabolism and secretion of lysosomal enzymes. More recent evidence has suggested that bisphosphonates also possess anticollagenase properties. In human studies, these agents resulted in enhanced alveolar bone status and density. (El-Shinnawi et al-2003) Alendronate was approved by the FDA in the USA in 1995 and studies have reported the effectiveness of ALN in preventing alveolar bone destruction associated with periodontal disease when administered systemically or locally to the target site. It is with this background and since limited studies have been conducted using alendronate as a graft material, this study was undertaken. Aim: To evaluate & compare the efficacy of Open flap debridement, Open flap debridement with Autogenous bone and Open flap debridement with Autogenous bone and Alendronate for the treatment of 2 walled and 3 walled intraosseous defects. Materials & Methods: 30 Subjects in the age range of 30 – 60 years were selected with chronic (clinical attachment loss > 5mm) periodontitis and probing depth ≥ 6mm were selected. Mandibular molars, with 2 or 3 walled intrabony defects were included in the study, with no history of metabolic disorders involving bone resorption. Radiographic evidence of bone defects were evident. Results: Mean measurements in the Group C for CAL gain (2.90 ±0.73), PD reduction (3.10 ±0.73) and RBH (2.40 ±0.96) were significantly greater with a p-value <0.05 compared to the mean measurements of CAL gain (3.80 ±0.78), PD reduction (4.40 ±1.17) and RBH (3.50 ±0.84) of Group A. Conclusion: Use of Alendronate- bisphosphonate as an additive material to autogenous bone grafts demonstrated improved results at 6 months and 9 months as compared to baseline.

PDF file: 

CALL FOR PAPERS

 

ONLINE PAYPAL PAYMENT

IJMCE RECOMMENDATION

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

EDITORIAL BOARD

CHUDE NKIRU PATRICIA
Nigeria
Dr. Swamy KRM
India
Dr. Abdul Hannan A.M.S
Saudi Arabia.
Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran